Dr. Brentjens on CD19-Targeted T Cells in Leukemia

Video

In Partnership With:

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.

Brentjens says researchers have found that CLL tumors are sensitive to C19-targeted T cells, as about 30-50% of treated patients achieve either a partial remission or complete remission. Brentjens says this patient population is heavily pretreated and that this level of response is remarkable.

In the setting of ALL, Brentjens says, there was a 100% response rate in the first 5 patients that were tested. Typically, a 20-30% response rate is expected.

Brentjens says these T cells can clearly provide clinical benefit to patients with leukemia.

Related Videos
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD